|
|
|
|
Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual
(Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-...
Company: Vertex Pharmaceuticals Inc.(VRTX) Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
Telaprevir Oral Presentations: 1.Study 107: "SVR with Telaprevir, Peginterferon Alfa-2a and Ribavirin in HCV Patients with Well-Characterized Prior Null Response, Partial Response, Viral Breakthrough or Relapse After PR"; April 15, 2010, 3:45 - 4:00 p...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.Vertex Pharmaceuticals Incorporated (Nasdaq Telaprevir Oral Presentations: 1.Study 107: SVR with Telaprevir, Peginterferon Alfa-2a and Ribavirin in HCV Patients with Well-Characterized Prior Null Response, Partial Response, Viral...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
Telaprevir Oral Presentations: 1.Study 107: SVR with Telaprevir, Peginterferon Alfa-2a and Ribavirin in HCV Patients with Well-Characterized Prior Null Response, Partial Response, Viral Breakthrough or Relapse After PR; April 15, 2010, 3:45 - 4:00 p.m....
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna,...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.- (BUSINESS WIRE) - (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
Vertex Pharmaceuticals Incorporated Rating: Related Stocks: Text Size: Vertex Pharmaceuticals Incorporated(VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
Companies mentioned in this article: Vertex Pharmaceuticals Incorporated CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.- (Business Wire) (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for...
|
|
|
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- (Nasdaq: VRTX - News) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual...
|
|
|
Idenix Announces Data Presentations at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)
Companies mentioned in this article: Idenix Pharmaceuticals, Inc.CAMBRIDGE, Mass., March 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the...
|
|
|
Sustained Virological Response to Pegylated Interferon and Ribavirin is Maintained During Long-Term Follow-up
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
EMERYVILLE, Calif., March 15 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
-- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy...
|
|
|
TCAD therapy superior to double combinations and monotherapy against influenza viruses
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy...
|
|
|
::: Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistan
EMERYVILLE, Calif., March 15 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
EMERYVILLE, Calif., March 15 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
EMERYVILLE, Calif., March 15 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
Companies mentioned in this article: Adamas Pharmaceuticals, Inc.EMERYVILLE, Calif., March 15 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that...
|
|
|
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy...
|
